RBS Global Big Pharma ETN

The investment seeks to replicate, net of expenses, the NYSE Arca Equal Weighted Pharmaceutical Total Return Index.
The index is designed to track the performance of the equity securities of a cross section of companies involved in various phases of development, production and marketing of pharmaceuticals, with the component securities represented in approximately equal dollar amounts.

Key stats

Management firm  Royal Bank of Scotland NV
Domicile  United States
Fund Administrator  Royal Bank of Scotland NV
Global Branding Name  RBS
Fund currency  USD
Launch Date  2011-10-21
ISIN  US78009P1350
Manager 1 Name  No Manager
Fund Strategy  Health
Benchmark  NYSE Arca EW Pharmaceutical TR USD
Fund Structure  Uncollateralized Debt Instrument
UCITS 3 compliant  no

Performance/Volatility

Return Date  2014-03-31
Return - 1 Month  -3.82%
Return - 2 Months  6.58 %
Return - 3 Months  9.79%
Return - 6 Months  26.06 %
Return - 9 months  35.28 %
Return - 12 Months  35.92%
Annualized return 24 months  27.82 %
Annualized return 36 months  0.00 %
Annualized return 48 months  0.00 %
Annualized return 60 months  0.00 %
Return 120 months  0.00 %
Annualized return since Inception  27.75%
Return YTD  9.79%

Charges

Initial  0.00 %
Maximum Managment Charge  0.60 %
Exit charge  0.00 %
Performance Fee  0.00 %

Contact

Contact Address  Coolsingel 119
Contact Address 2  Postbus 1230
Contact Address 3  3000 BE Rotterdam
Contact city  Netherlands
Contact country  Netherlands
Fund Admin Group  Royal Bank of Scotland NV
Web Address  www.rbs.com
Email contact  RBSNetherlands@rbs.com
Custodian  The Bank of New York Mellon
Phone  31204649999

Price

Last Price Date  2014-04-10
Pre-tax nav  43.65
Pre-tax offer  46.65
Pre-tax bid  40.87
Pre-tax mid  0.00
Post-tax nav  0.00
Post-tax offer  0.00
Post-tax bid  0.00
Price change  $-1.28
Price change (percentage)  -2.85 %
Guaranteed NAV  0.00000
Close Price  0.00

Funds Disclaimer

© 2011 - Morningstar UK Limited. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed (save (i) as incidentally necessary in the course of viewing it on-line (ii) in the course of printing off single copies of web pages on which it appears for the use of those authorised to view it on-line), or adapted in any way (3) is not warranted to be accurate, complete or timely. This Morningstar-sourced information is provided to you by GFM Ltd and is at your own risk. You agree that Morningstar and or GFM Ltd are not responsible for any damages or losses arising from any use of this information and that the information must not be relied upon by you the user without appropriate verification. GFM Ltd informs you as follows: (i) The information provided should not form the sole basis of any investment decision (ii) no investment decision should be made in relation to any of the information provided other than on the advice of a professional financial advisor; (iii) past performance is no guarantee of future results; and (iv) the value and income derived from investments can go down as well as up.
For fund additions and/or data corrections please contact dataquestions@morningstar.com

Ratings Disclaimer

© 2010 - 2011 Morningstar UK Limited. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
For fund additions and/or data corrections please contact dataquestions@morningstar.com

All our data is licensed from Morningstar UK Ltd. Important legal information